No abstract available.
Brain ; Scleroderma, Localized ; Scleroderma, Systemic

No abstract available.
Humans ; Scleroderma, Systemic

No abstract available.
Antibodies, Antinuclear* ; Scleroderma, Systemic*

No abstract available.
Lung* ; Pneumothorax* ; Scleroderma, Systemic*

42 patients were diagnosed as scleroderma and treated at Bach Mai Hospital in three years (1991-1993). 90.47% was female, the age ranged from 18 to 63 years. The control group consisted of 20 healthy normal persons. Results: the rate of anti dsDNA positive with serum 1/10 was 30.95%; the rate of anti ANA positive with serum 1/40 was 71.42% in the patients with scleroderma. In the control group, there is no person who had anti dsDNA positive with serum 1/10. The rate of anti ANA positive with serum 1/40 is 10%. Positive anti dsDNA rate is not high (30.95%). There is no case of scleroderma which had negative anti ANA but positive anti dsDNA in the patients group. The appearance of anti dsDNA and anti ANA with digestive and cardiovascular disorder had a high rate. Anti ANA is more valuable in following the nephroinjuries in the scleroderma than dsDNA
Scleroderma, Systemic ; Diagnosis ; Therapeutics

Scleroderma is the autoimmune diseases. It has clinical characteristics of other autoimmune diseases such as: systemic lupus erythmatosus, juvenile rheumatoid arthritis…Appearance of antinuclear factors, rheumatofactors and increased blood gamma globulin showed that the immunity in this disease is abnormal. Study on 20 patients with scleroderma who were treated at the Allergy Department in two years (1984-1985) showed that: the ratio of leukocyte in the patients was not lower than that in control groups; the percentage of T lymph in peripheral blood was lower; B lymph in peripheral blood increased lightly; T gamma in peripheral blood was lower; the percentage of lymphocyte transformation with Con A and lymphocyte transformation with PHA were lower; lymphocyte transformation with PWM increased
Scleroderma, Systemic ; Diagnosis

No abstract available.
Debridement* ; Scleroderma, Systemic* ; Upper Extremity*

No abstract available.
Debridement* ; Scleroderma, Systemic* ; Upper Extremity*

No abstract available.
Arthritis, Psoriatic* ; Macrophages* ; Scleroderma, Systemic*

Background: Scleroderma is a rare autoimmune disease occurs with an annual rate of about 2-20 cases / 1 million people. Objectives: To evaluate the common clinical and laboratory manifestaions of scleroderma associated renal disease. Subjects and method: A restrospective study of clinical, urinary analysis, biochemical and blood count analysis and renal artery dopper ultrasonography indexes in 147 patients with scleroderma. Results: The commonest nonrenal clinical manifestations were skin thickening (100%), pigmentation (71,43%), arthalgia/ arthritis (83%), Raynaud phenomenon (62,58%) and gastroentrological syndrome (50,34%). 11,56% of patients had signs and symptoms of kidney involvement such us hypertension (10,2%), edema (9,52%), oliguria (3,4%). 14,29%, 10,88% and 18,18% of patients had abnomalities on urinary analysis, increased blood urea and renal artery stenosis on dooper ultrasonography, respectively. Conclusion: 11,56% of patients had rena manifestationsin clinical, the commonest is hypertension, edema and oliguria. 14,29%, 10,88% and 18,18% of patients had positive proteinuria of hematuria, increased blood urea and renal artery stenosis on dopper ultrasonography, respectively.
Kidney Diseases/ epidemiology ; Scleroderma ; Systemic ;